Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome - PubMed (original) (raw)
Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome
R B Barnes et al. N Engl J Med. 1989.
Abstract
To investigate the basis of polycystic ovary syndrome, we examined the responses of patients to nafarelin, a specific gonadotropin-releasing-hormone agonist, given to stimulate pituitary and gonadal secretion. We compared 16 normal women in the follicular phase, 5 normal men, 8 women with polycystic ovary syndrome, and 1 woman with polycystic ovary syndrome caused by a 3 beta-hydroxysteroid dehydrogenase deficiency. After 100 micrograms of nafarelin was given subcutaneously, serum follicle-stimulating hormone and luteinizing hormone increased rapidly to peak levels within four hours. The women with polycystic ovary syndrome had a pattern similar to that of the men, with greater early luteinizing-hormone responses (30 minutes to 1 hour) and lower peak follicle-stimulating-hormone responses than normal women (P less than 0.05). Patients with polycystic ovary syndrome responded to gonadotropin stimulation with normal to increased production of plasma estrogens and increased levels of androstenedione at 16 to 24 hours (P less than 0.05). Elevated production of 17 alpha-hydroxyprogesterone was found in all the women with polycystic ovary syndrome and in the men. These abnormal responses were unchanged by pretreatment with dexamethasone to suppress adrenal function. In the patient with the 3 beta-hydroxysteroid dehydrogenase deficiency, both basal and stimulated plasma levels of delta 5-3 beta-hydroxysteroids before the enzymatic block were elevated, whereas plasma levels of 17 alpha-hydroxyprogesterone and androstenedione--the steroids immediately beyond the block--were low. We conclude that women with polycystic ovary syndrome have masculinized pituitary and ovarian responses to stimulation by nafarelin. Our findings suggest that the regulation of the ovarian 17-hydroxylase and C-17,20-lyase activities is abnormal in such women.
Similar articles
- Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism.
Rosenfield RL, Barnes RB, Ehrmann DA. Rosenfield RL, et al. J Clin Endocrinol Metab. 1994 Dec;79(6):1686-92. doi: 10.1210/jcem.79.6.7989476. J Clin Endocrinol Metab. 1994. PMID: 7989476 - Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome.
Gonzalez F, Hatala DA, Speroff L. Gonzalez F, et al. Am J Obstet Gynecol. 1991 Sep;165(3):535-45. doi: 10.1016/0002-9378(91)90280-5. Am J Obstet Gynecol. 1991. PMID: 1832519 - Gonadotropin-releasing hormone agonist as a probe for the pathogenesis and diagnosis of ovarian hyperandrogenism.
Rosenfield RL, Ehrmann DA, Barnes RB, Sheikh Z. Rosenfield RL, et al. Ann N Y Acad Sci. 1993 May 28;687:162-81. doi: 10.1111/j.1749-6632.1993.tb43864.x. Ann N Y Acad Sci. 1993. PMID: 8323171 Review. - Mechanisms of hypothalamic-pituitary-gonadal disruption in polycystic ovarian syndrome.
Barontini M, García-Rudaz MC, Veldhuis JD. Barontini M, et al. Arch Med Res. 2001 Nov-Dec;32(6):544-52. doi: 10.1016/s0188-4409(01)00325-3. Arch Med Res. 2001. PMID: 11750729 Review.
Cited by
- Disordered follicle development.
Chang RJ, Cook-Andersen H. Chang RJ, et al. Mol Cell Endocrinol. 2013 Jul 5;373(1-2):51-60. doi: 10.1016/j.mce.2012.07.011. Epub 2012 Jul 31. Mol Cell Endocrinol. 2013. PMID: 22874072 Free PMC article. Review. - Irpex lacteus polysaccharide exhibits therapeutic potential for ovarian fibrosis in PCOS rats via the TGF-_β_1/smad pathway.
Zhou YY, Wu YQ, Chong CJ, Zhong SM, Wang ZX, Qin XH, Liu ZQ, Liu JY, Song JL. Zhou YY, et al. Heliyon. 2023 Jul 27;9(8):e18741. doi: 10.1016/j.heliyon.2023.e18741. eCollection 2023 Aug. Heliyon. 2023. PMID: 37554783 Free PMC article. - Incredible Combination of Lifestyle Modification and Herbal Remedies for Polycystic Ovarian Syndrome Management.
Balkrishna A, Rana M, Mishra S, Srivastava D, Bhardwaj R, Singh S, Rajput SK, Arya V. Balkrishna A, et al. Evid Based Complement Alternat Med. 2023 Jun 20;2023:3705508. doi: 10.1155/2023/3705508. eCollection 2023. Evid Based Complement Alternat Med. 2023. PMID: 37383339 Free PMC article. Review. - Hirsutism: pilosebaceous unit dysregulation. Role of peripheral and glandular factors.
Toscano V. Toscano V. J Endocrinol Invest. 1991 Feb;14(2):153-70. doi: 10.1007/BF03350293. J Endocrinol Invest. 1991. PMID: 2061571 Review. No abstract available. - Naturally Occurring and Experimentally Induced Rhesus Macaque Models for Polycystic Ovary Syndrome: Translational Gateways to Clinical Application.
Abbott DH, Rogers J, Dumesic DA, Levine JE. Abbott DH, et al. Med Sci (Basel). 2019 Nov 27;7(12):107. doi: 10.3390/medsci7120107. Med Sci (Basel). 2019. PMID: 31783681 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical